Debra Michelle Hunter is a pharmacist who is specialized in Oncology in Midland, Texas. Patients can reach her at 301 North 'n' St, Midland or contact her on 432-688-0822. Active license number of Debra Michelle Hunter is 33038 for Oncology in Texas. Debra Michelle Hunter is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Debra Michelle Hunter speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Debra Michelle Hunter
Specialization:
Oncology
Credentials:
RPH
Gender:
Female
Location:
301 North 'n' St, Midland, Texas, 79701
Phone:
432-688-0822
Fax:
432-687-0268
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Debra Michelle Hunter are as mentioned below.
NPI Number:
1205901139
NPI Enumeration Date:
24 Nov, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Debra Michelle Hunter are as mentioned below.
Specialization
License Number
State
Status
Oncology
33038
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
4304 Skyline Dr, Midland, Texas
Zip:
79707-3636
Phone Number:
432-689-3839
Fax Number:
--
Patients can reach Debra Michelle Hunter at 301 North 'n' St, Midland, Texas or can call on phone at 432-688-0822.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.